Femasys Q3 net loss widens to $2.98M; FemBloc trial enrollment complete, FemaSeed trial updated

FEMASYS INC

2022-Q3 EPS reported -$0.72 revenue$971,974

Q3 net loss $2.98M ($0.25/share) vs $2.26M ($0.19) YoY; revenue $347K (+28.9% on FemVue).
FemBloc Stage 2 enrollment complete; IDE for pivotal trial on track for Q1 2023.
FemaSeed trial updated to focus on male factor infertility; expects enrollment completion in 2023.
FemCerv commercially launched; FemCath expected by year-end.
Cash $16.0M at Sept 30, down from $24.8M at Dec 31, 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FEMASYS INC reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Femasys Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022 and provided a corporate update.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-22-040811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.